Aprepitant

Aprepitant (MK-0869) is a selective and high-affinity neurokinin 1 receptor antagonist with a Kd of 86 pM.

Product Specifications

CAS Number

[170729-80-3]

Product Name Alternative

MK-0869; MK-869; L-754030

UNSPSC

12352005

Hazard Statement

H302, H315, H319, H335

Target

Antibiotic; Bacterial; HIV; Neurokinin Receptor

Type

Reference compound

Related Pathways

Anti-infection; GPCR/G Protein; Neuronal Signaling

Applications

Cancer-programmed cell death

Field of Research

Neurological Disease; Endocrinology; Cancer

Assay Protocol

https://www.medchemexpress.com/Aprepitant.html

Purity

99.82

Solubility

DMSO : 50 mg/mL (ultrasonic)

Smiles

O=C1NC(CN2[C@H]([C@@H](O[C@@H](C3=CC(C(F)(F)F)=CC(C(F)(F)F)=C3)C)OCC2)C4=CC=C(F)C=C4)=NN1

Molecular Formula

C23H21F7N4O3

Molecular Weight

534.43

Precautions

H302, H315, H319, H335

References & Citations

[1]Martinez AN, et al. Aprepitant limits in vivo neuroinflammatory responses in a rhesus model of Lyme neuroborreliosis. J Neuroinflammation. 2017 Feb 15;14 (1) :37.|[2]Bayati S, et al. Inhibition of tachykinin NK1 receptor using aprepitant induces apoptotic cell death and G1 arrest through Akt/p53 axis in pre-B acute lymphoblastic leukemia cells. Eur J Pharmacol. 2016 Nov 15;791:274-283.|[3]Mannangatti P, et al. Differential effects of aprepitant, a clinically used neurokinin-1 receptor antagonist on the expression of conditioned psychostimulant versus opioid reward. Psychopharmacology (Berl) . 2017 Feb;234 (4) :695-705.|[4]Barrett JS, et al. Pharmacologic rationale for the NK1R antagonist, aprepitant as adjunctive therapy in HIV. J Transl Med. 2016 May 26;14 (1) :148.